Richard Maury Stone, MD, is director of the Adult Leukemia Program at the Dana-Farber Cancer Institute, an attending physician at Brigham and Womens Hospital and professor of medicine at Harvard Medical School in Boston, Massachusetts. Dr Stone cares for patients with acute and chronic leukemias, myelodysplasia, and myeloproliferative disorders. Dr Stone conducts clinical and translational research with the goal of deriving better outcomes for patients with these disorders. His laboratory research focuses on the mechanism of leukemic cell differentiation, with the ultimate goal of producing new cancer therapies. Dr Stone earned his AB in biochemistry at Harvard Medical College in Cambridge, Massachusetts and his MD at Harvard Medical School in Boston. After graduating, he completed his internship and residencies in internal medicine at Brigham and Womens Hospital in Boston, where he was designated chief medical resident. Dr Stone trained as a Fellow in Medical Oncology at the Dana-Farber Cancer Institute.Dr Stone is a recipient of the American Cancer Society Clinical Career Development Award, the National Institutes of Health (NIH) Clinical Investigator Award, Upjohn Outstanding Achievement in Cancer Research, and NIH FIRST Award. He serves as vice-chair of the Leukemia Committee of the National Cancer Cooperative Trials Group, Cancer and Leukemia Group B (CALGB). Dr Stone is a member of the Medical Oncology Board of the American Board of Internal Medicine and serves as chairman of the Medical Advisory Board for the International Aplastic Anemia and Myelodysplastic Syndrome Foundation, a patient advocacy group. Dr Stone's articles, which are primarily devoted to leukemia and related topics, are published in prestigious journals such as Blood, the Journal of Clinical Oncology, Nature Genetics, and the New England Journal of Medicine, among others.